Special Drug Use Surveillance of Entresto Tablets (Hypertension) (ENLIGHT)
Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT
Sponsor: Novartis Pharmaceuticals
Listed as NCT05976230, this observational or N/A phase trial focuses on Hypertension and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 13 times since 2023, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Aug 2025 — Sep 2025 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Feb 2025 — Aug 2025 [monthly]
Active Not Recruiting
-
Nov 2024 — Feb 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
▶ Show 8 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
-
May 2024 — Jun 2024 [monthly]
Recruiting
-
Mar 2024 — May 2024 [monthly]
Recruiting
-
Jan 2024 — Mar 2024 [monthly]
Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting
-
Oct 2023 — Dec 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aiko-gun, Japan , Akashi, Japan , Akishima, Japan , Amagasaki, Japan , Anjo, Japan , Asaka, Japan , Bandō, Japan , Chikusei, Japan , Edogawa-ku, Japan , Fujimino, Japan and 74 more locations